CDK 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (mBC): The Likelihood of being Helped or Harmed (LHH) as a patient-centred tool to assess clinical impact and safety

被引：0
|
作者：
Mastrantoni, L. [1 ]
Orlandi, A. [2 ]
Palazzo, A. [2 ]
Garufi, G. [1 ]
Fabi, A. [3 ]
Daniele, G. [4 ]
Giannarelli, D. [5 ]
Tortora, G. [6 ]
Bria, E. [6 ]
机构：
[1] Univ Cattolica Sacro Cuore, Med Oncol Dept, Rome, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Women Children & Publ Hlth Sci, Precis Med Breast Unit, Sci Directorate, Rome, Italy
[4] Fdn Policlin Univ Agostino Gemelli IRCCS, UOC Phase I, Rome, Italy
[5] Fdn Policlin Univ Agostino Gemelli IRCCS, Biostat, Rome, Italy
[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Unit, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
234P
引用
收藏
页码：S644 / S644
页数：1
相关论文
共 50 条
  • [1] RETRACTED: Resistance to CDK4/6 inhibitors (CDK4/6i): The clinical usefulness of liquid biopsy in metastatic breast cancer (mBC). (Retracted Article)
    Raimondi, Lucrezia
    Di Benedetto, Laura
    Naso, Giuseppe
    Raimondi, Filippo Maria
    Di Rocco, Arianna
    Giaconi, Laura
    Lazzeroni, Rachele
    Spinelli, Gian Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
    Mastrantoni, Luca
    Orlandi, Armando
    Palazzo, Antonella
    Garufi, Giovanna
    Fabi, Alessandra
    Daniele, Gennaro
    Giannarelli, Diana
    Tortora, Giampaolo
    Bria, Emilio
    ECLINICALMEDICINE, 2023, 56
  • [3] Predictors of non-receipt of first-line CDK 4/6 inhibitors (CDK4/6i) among patients with metastatic breast cancer (MBC).
    Lee, Kimberley T.
    Chiao, Elaine
    Lim, David
    Mouslim, Morgane
    Wang, Chenguang
    Mangini, Neha
    Stearns, Vered
    Smith, Karen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] RETRACTION: Resistance to CDK4/6 inhibitors (CDK4/6i): The clinical usefulness of liquid biopsy in metastatic breast cancer (mBC) (Retraction of Vol 39, Pg 1053, 2021)
    Raimondi, Lucrezia
    Giaconi, Laura
    Spinelli, Gian Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (35) : 3999 - 3999
  • [5] Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Mai, Nicholas
    dos Anjos, Carlos H.
    Razavi, Pedram
    Safonov, Anton
    Patil, Sujata
    Chen, Yuan
    Drago, Joshua Z.
    Modi, Shanu
    Bromberg, Jacqueline F.
    Dang, Chau T.
    Liu, Dazhi
    Norton, Larry
    Robson, Mark
    Chandarlapaty, Sarat
    Jhaveri, Komal
    NPJ BREAST CANCER, 2024, 10 (01)
  • [6] Comparison of treatment-related adverse events (TRAE) of different CDK4/6 inhibitors (CDK4/6i) in metastatic breast cancer (MBC): A network meta-analysis.
    Desnoyers, Alexandra
    Nadler, Michelle
    Kumar, Vikaash
    Saleh, Ramy
    Amir, Eitan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
    Ettl, Johannes
    Huober, Jens
    Lueftner, Diana
    Marme, Frederik
    Wuerstlein, Rachel
    BREAST CARE, 2017, 12 (02) : 118 - 120
  • [8] The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)
    Eiger, Daniel
    Wagner, Marcio
    Ponde, Noam F.
    Nogueira, Melanie S.
    Buisseret, Laurence
    de Azambuja, Evandro
    ACTA ONCOLOGICA, 2020, 59 (06) : 723 - 725
  • [9] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [10] Beyond First Line CDK4/6 Inhibitors (CDK4/6i) and Aromatase Inhibitors (AI) in Patients with Oestrogen Receptor Positive Metastatic Breast Cancer (ER plus MBC): The Guy's Cancer Centre Experience
    Gousis, C.
    Michoglou, K.
    Lowe, H.
    Kapiris, M.
    Angelis, V.
    CLINICAL ONCOLOGY, 2022, 34 (04) : E178 - E178
12345